ABUS vs CBRE · P/E 5.4, rev $6.2M vs P/E 43, rev $35.77B
Arbutus Biopharma Corp (ABUS) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the ABUS and CBRE stock pages for the full models.
Not investment advice.